Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

In vitro potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing Enterobacterales

Antimicrobial Agents and Chemotherapy(2023)10.1128/aac.00440-23Source: DataRank Database

In vitro potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing Enterobacterales is a research paper published in Antimicrobial Agents and Chemotherapy (2023). On theSindex it has a DataRank of 0. It has been cited 39 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access39 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 3.28)OA: hybridTopics (53)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Mariana Castanheira ORCID,Jill Lindley ORCID,Debora Rubio-Aparicio,Kirk Nelson ORCID,Ruslan Tsivkovski

Live enrichment

PubMed:37800963 PMC:PMC10648875 OpenAlex:https://openalex.org/W4387392888

HHS | Biomedical Advanced Research and Development Authority

Grant: HHSO100201600026C

NIH HHS

Grant: S10 OD026929

National Institutes of Health

Grant: 1S10OD026929-01

Illumina NovaSeq 6000 Sequencing System

FWCI

3.28

Citation Percentile

0.9%

Citation Trend

2024

2025

2026

hybridLicense: cc-by

journalhttps://doi.org/10.1128/aac.00440-23

HYBRIDhttps://doi.org/10.1128/aac.00440-23

publisherhttps://doi.org/10.1128/aac.00440-23

publisherhttps://journals.asm.org/doi/pdf/10.1128/aac.00440-23

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37800963

Fields of Study

Antibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyPneumonia and Respiratory InfectionsMedicine0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

Cefepimebeta Lactam AntibioticsAnti-Bacterial Agentsbeta-LactamasesBorinic AcidsCarboxylic AcidsLactamsMicrobial Sensitivity TestsSerineCarbapenemsAzabicyclo Compoundsbeta-Lactamase Inhibitors

Keywords

PotencyCarbapenemMeropenemAntibioticsMicrobiologyIn vitroMinimum inhibitory concentrationCephemPharmacologyChemistryBiologyBiochemistryAntibiotic resistanceCreCarbapenemasesMetallo-β-lactamasesAvibactamRelebactamVaborbactamTaniborbactamXeruborbactamLactamsCarboxylic AcidsMicrobial Sensitivity Testsbeta-LactamasesAnti-Bacterial AgentsCarbapenemsMechanisms of ResistanceSerinebeta-Lactamase InhibitorsCefepimeBorinic AcidsAzabicyclo Compoundsbeta Lactam Antibiotics

Sustainable Development Goals

SDG 3: 3. Good health

In vitro potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing Enterobacterales

FAIR Checklist

Authors (10)

Funding (3 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)